Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAILOR: Ranibizumab Safety in AMD
NCT00251459Phase 3Completed
- Sponsor
- Genentech
- Start
- Nov 2005
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, single-blind trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (3 cohorts), sponsored by Genentech. Primary endpoint: Incidence of Serious Adverse Events at 12 months. Started Nov 2005; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00251459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251459.